Sartorius falls after 12-m B2B ratio commentary

** Sartorius SRT falls 4.6% despite a rise in H1 revenue and profits, with analysts at J.P. Morgan pointing to the company's comment on the rolling 12 month B2B ratio being above 1 and consistently improving

** "Overall, while 2Q was solid on u/l EBITDA, we infer the rolling 12M B2B comment to imply BPS B2B in 2Q below 1 and given we do not expect consensus to move post this update, we expect the shares to underperform today," they say

** Group revenue rose 6.1% in constant currencies to 1.77 billion euros in H1, while underlying EBITDA rose significantly by 11.9% to 527 million euros

** Sartorius shares hit their lowest level in over three months

** Shares in French subsidiary Sartorius Stedim Biotech are down 6.7%